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Digital Detection of Exosomes by 
Interferometric Imaging
George G. Daaboul1,*, Paola Gagni2,*, Luisa Benussi3, Paolo Bettotti4, Miriam Ciani3, 
Marina Cretich2, David S. Freedman1, Roberta Ghidoni3, Ayca Yalcin Ozkumur5, Chiara Piotto4, 
Davide Prosperi6, Benedetta Santini6, M. Selim Ünlü7 & Marcella Chiari2
Exosomes, which are membranous nanovesicles, are actively released by cells and have been attributed 
to roles in cell-cell communication, cancer metastasis, and early disease diagnostics. The small size 
(30–100 nm) along with low refractive index contrast of exosomes makes direct characterization and 
phenotypical classification very difficult. In this work we present a method based on Single Particle 
Interferometric Reflectance Imaging Sensor (SP-IRIS) that allows multiplexed phenotyping and digital 
counting of various populations of individual exosomes (>50 nm) captured on a microarray-based 
solid phase chip. We demonstrate these characterization concepts using purified exosomes from a HEK 
293 cell culture. As a demonstration of clinical utility, we characterize exosomes directly from human 
cerebrospinal fluid (hCSF). Our interferometric imaging method could capture, from a very small hCSF 
volume (20 uL), nanoparticles that have a size compatible with exosomes, using antibodies directed 
against tetraspanins. With this unprecedented capability, we foresee revolutionary implications in 
the clinical field with improvements in diagnosis and stratification of patients affected by different 
disorders.
Exosomes are a class of membranous extracellular vesicles (EV) that originate from inward budding of the endo-
somal compartment within a cell1. The interest of scientists and physicians in EVs has grown dramatically over 
the past decade in response to the discovery that these vesicles transfer mRNA, miRNA, and protein from the cell 
of origin to recipient cells2, serving a new route for cell-to-cell communication. Presence of exosomes in circu-
lating bodily fluids, including blood3, urine4 and saliva5, suggests that minimally-invasive diagnosis of a number 
of diseases can be achieved through detection of these vesicles6–9. In particular, EVs are considered valuable for 
liquid biopsies in cancer diagnosis since they carry molecular and proteomic cargo from their tumour cell of 
origin10. In human CSF, EVs are rich reservoirs of biomarkers for neurological disorders and there is increas-
ing evidence that deregulation of EVs secretion play a pathological role in neurodegenerative diseases such as 
Alzheimer’s disease (AD) and Frontotemporal dementia (FTD)11–15.
The limited utility of exosomes in diagnostics is mainly due to difficulties in specifically characterizing them 
using a scalable phenotyping method. Exosomes have diameters in the range from 30–100 nanometers, i.e., 
which is too small to be accurately sized by conventional methods such as optical microscopy and flow cytometry 
(FC) without labels. Alternatively, immunocapturing of exosomes on antibody coated beads16 facilitates analysis 
by FC. However, such indirect detection is not quantitative and measurements are further complicated due to 
aggregation of exosome-bead complexes. A number of references report on the direct visualization of exosomes 
with electron microscopy17 but this technique is not suitable for large scale application due to its complexity and 
low-throughput. Western blot is currently used to verify that isolated vesicles are indeed exosomes through char-
acterization of exosomal proteins. However, even the analysis for a single antigen demands large amounts of puri-
fied exosomal proteins isolated by extensive and time-consuming (hours to days) procedures. Such requirements 
limit the throughput and substantially increase the cost for multi-parameter measurements.
1Nexgen Arrays, Boston, Massachusetts 02215, USA. 2Consiglio Nazionale delle Ricerche, Istituto di Chimica 
del Riconoscimento Molecolare (ICRM), Milano, Italy. 3Molecular Markers Laboratory, IRCCS Istituto Centro San 
Giovanni di Dio Fatebenefratelli, Brescia, Italy. 4Nanoscience Laboratory, Department of Physics, University of 
Trento, Povo (TN) Italy. 5Department of Electrical and Electronics Engineering, Bahçeşehir University, Istanbul, 
Turkey. 6Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milano, Italy. 7Department of 
Electrical and Computer Engineering, Boston University, Boston, Massachusetts 02215, USA. *These authors 
contributed equally to this work. Correspondence and requests for materials should be addressed to G.G.D. (email: 
gdaaboul@nexgenarrays.com) or M. Chiari (email: marcella.chiari@icrm.cnr.it)
Received: 20 June 2016
accepted: 26 October 2016
Published: 17 November 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:37246 | DOI: 10.1038/srep37246
The efforts in development of new tools for analysis of exosomes have led to a number of innovative tech-
nologies with potential clinical applications. Two recently commercialized nanoparticle detection technologies 
are typically utilized in characterization of exosomes: Nanoparticle Tracking Analysis (NTA) (NanoSight) and 
conductivity measurements across a porous membrane (qNano by Izon Science Ltd). NTA is the most commonly 
used method for determining size distribution and concentration of isolated exosomes in suspension where par-
ticle size is calculated based on Brownian motion18. In order to overcome the limitations of conventional NTA 
to determine the cell of origin and to distinguish between different vesicles types (i.e. EVs, lipids and protein 
aggregates), a short wavelength (405-nm blue-violet) laser and a high sensitivity camera to detect fluorescent 
particles19 are incorporated to the optical system. In this modality, combining NTA with fluorescence measure-
ments, only exosomes labeled with specific fluorescent antibodies are detected, thus allowing their phenotype to 
be determined. Despite this improvement, challenges persist due to the difficulty in multiplexing and large vol-
ume requirements. TRPS measures the size and concentration of a nanoparticle suspension through conductivity 
changes through a porous membrane20, but no information is provided on the nature of the protein expressed on 
the surface. Both techniques provide valuable information but they cannot identify and simultaneously pheno-
type exosomes, which is an important limitation, as the actual presence of certain surface proteins would allow 
the identification of exosomes originating from different cell sources.
There are several emerging new techniques for label-free detection of exosomes. Recently, a real-time, 
label-free sensing of single exosomes in serum using antibody functionalized micro-toroid optical resonators 
has been introduced21. Although highly sensitive, such high-Q optical resonators have significant challenges of 
identifying size of captured particles in a complex solution and difficulty of multiplexing.
Another real-time, label-free exosome assay based on surface plasmon resonance (SPR) has been demonstrated22. 
The plasmonic sensor comprises of an array of periodic nanoholes patterned in a metal film. Binding to the sen-
sor surface is monitored through change in optical transmission due to change of refractive index at the sensor 
surface. The technology offers high sensitivity and enables continuous and real-time monitoring of molecular 
binding. However, this sensor technology does not provide any information about the size of the captured target 
to indicate if the signal is due to capture of intact vesicles or soluble proteins.
The study presented in this paper demonstrates a label-free detection platform for routine analysis of 
exosomes using antibody-based exosome arrays and interferometric digital detection of individual nanoparticles 
(NPs). The technique enables the fractionation of populations of exosomes that exhibit specific surface proteins 
allowing better understanding of EV heterogeneity. By comparing the phenotype and size of EVs present in body 
fluids of healthy donors and patients with different diseases, the platform is expected to accelerate the translation 
of exosome studies from research into clinics. The technology proposed in this article, based on interferometric 
imaging, can detect individual nanovesicles on a capture surface in a microarray format and, potentially, assess 
their size. The principle of Single Particle Interferometric Reflectance Imaging Sensor (SP-IRIS) technology is 
the enhanced contrast in the scattering signal from nanoparticles that is generated using a layered substrate. The 
technology has so far mostly been applied to the simultaneous detection of multiple viruses in serum or whole 
blood23. By employing affinity-based capture, size discrimination, and a digital detection scheme to count single 
virus particles, a robust and sensitive virus/nanoparticle sensing assay was established for targets in complex sam-
ples. The SP-IRIS platform has been previously shown to count and size individual viruses from complex solu-
tions at low concentrations down to 5 × 103 PFU/mL in serum23. In this work, we demonstrate that the SP-IRIS 
platform can count and phenotype multiple types of exosomes from a single sample. The contrast of the detected 
nanovesicles in the SP-IRIS image can be used to estimate the relative size of the nanovesicles, while their spatial 
location in the array provides information on the exosomes’ phenotype. The novelty of this work is that a single 
instrument provides the size and multi-phenotype information from the same exosome preparation.
Materials and Methods
Materials. Phosphate buffered saline (PBS), Trizma base (Tris), HCl, ethanolamine, ammonium sulphate, 
and Tween-20 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Copoly(DMA-NAS-MAPS) (MCP-2) 
was purchased from Lucidant Polymers Inc. (Sunnivale, CA, USA). SP-IRIS printed microarrays were provided 
by nanoView Diagnostics Inc.
Monoclonal antibodies against the human tetraspanins CD63, CD81, CD9, and CD171 were purchased from 
Nexgenarrays LLC (Boston, MA). Pure whole molecules IgG from Goat (R&D Biosystems) or Rabbit (Jackson 
Immunoresearch, West Grove, PA, USA) were used as negative controls.
Artificial cerebrospinal fluid was composed of NaCl (120 mM), NaHCO3 (25 mM), KCl (2.5 mM), NaH2PO4 
(1 mM), CaCl2 (2.5), MgCl2 ⋅ 6 H2O (1 mM), Glucose (20 mM) and Human Serum Albumin (0.4 mg/mL), all 
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Exosome isolation from human biological samples. HEK 293 (Human Embryonic Kidney 293) 
cell line were cultured in Minimum Essential Medium (MEM, Life Technologies) supplemented with 10% 
Fetal Bovine Serum (EuroClone S.p.A.), 1% Penicillin/Streptomycin solution (Carlo Erba Reagents), 2 mM 
L-glutamine (Carlo Erba Reagents), 1% MEM non-essential Amino Acids solution (Carlo Erba Reagents), at 
37 °C in 5% CO2/95% air. Cells were grown to complete confluence and incubated in serum-free medium for 
72 h. Conditioned media were pooled and centrifuged to obtain exosomes according to a standard protocol24. 
Briefly, conditioned media were collected and spun at 300 × g for 10 min three times. The supernatants were then 
sequentially centrifuged at 1200 × g for 20 min and again at 10,000 × g for 30 min followed by ultracentrifugation 
at 110,000 × g for 60 min (T-8100 rotor) (Sorvall). All centrifugations were performed at 4 °C. The 110,000 × g 
pellet was then resuspended in PBS (5 uL per Petri 100 mm dish) and then serially diluted for NTA and SP-IRIS 
analyses.
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Human cerebrospinal fluid (hCSF) samples were obtained from patients affected by neuropsychiatric disor-
ders, selected from the Fatebenefratelli Biobank. All experiments were performed in accordance with the rules of 
the local ethycal committee of Fatebenefratelli Hospital (Brescia Italy) that approved the study (Prot. N. 2/92/p/
rm; Prot. N. 52/2014; Prot. N. 44/2016).
Informed consent was obtained from all subjects. For Western blot analysis exosomes were isolated from 
1.8 mL hCSF by serial centrifugation as described above; for further characterization, the 110,000 x g pellet 
obtained from 12 mL of hCSF was loaded into a continuous 0.25–2 M sucrose gradient and after 16 h of centrifu-
gation at 200,000 × g (TH-641 rotor) (Sorvall), fractions were collected from the top of the gradient, diluted with 
PBS and spun at 110,000 × g for 70 min. All centrifugations were performed at 4 °C. The pelleted fractions were 
analyzed by Western Blot using the TSG101 monoclonal antibody (4A10) (Abcam), the Flotillin-2/ESA antibody 
(BD Biosciences), the cystatin C polyclonal antibody (Upstate Biotechnology), and monoclonal calnexin antibody 
(Transduction Laboratories).
Nanoparticle Tracking Analysis (NTA).  Nano-Sight LM10 instrument (Malvern, Worcestershire, UK) 
was used to analyze suspensions containing vesicles. The diluted samples were illuminated by a monochromatic 
laser beam at 532 nm to register a 60 second video taken with a mean frame rate of 30 frames/s. The NTA software 
(version 3.0, NanoSight) was used to analyze EVs samples, optimized to first identify and then track each particle 
on a frame-by-frame basis, and its Brownian movement is tracked and measured from frame to frame. Particle 
size was determined applying the two-dimensional Stokes–Einstein equation based on the velocity of particle 
movement. From each video, the mean, mode, and median EVs size was used to calculate samples concentration 
expressed in nanoparticles/mL.
Coating of microarray silicon chips with copoly-(DMA-NAS-MAPS).  Silicon chips were coated 
according to the protocol described by M. Cretich et al.25. Briefly, silicon chips were immersed in a copoly-
(DMA-NAS-MAPS)26 solution (1% w/v in 0.9 M (NH4)2SO4) for 30 min. The chips were then rinsed with water, 
dried under nitrogen and cured for 15 min under vacuum at 80 °C.
Brief description of the SP-IRIS platform. SP-IRIS measurements were carried out using a NVDX10 
reader (Nexgenarrays LLC, Boston, MA). The reader automatically acquires interferometric images of the 
microarray. Nanoparticles bound to the surface of the sensor appear as bright diffraction limited spots that are 
quantified using the NVDX10 analysis software. NVDX10 software counts nanoparticles captured on the anti-
body spots within a user defined particle contrast window. For exosome analysis the size window was selected as 
1–20% to include particle sizes from 50–200 nm.
Digital detection of exosomes either from HEK cell line and hCSF using SP-IRIS.  Capture anti-
bodies against human CD63, CD81, CD9, CD171 together with negative controls IgG (Goat or Rabbit, pure 
whole molecules) were arrayed on copoly-(DMA-NAS-MAPS)-coated SP-IRIS patterned silicon chips, with 
100 nm oxide layer thickness, using a SciFlexArrayer S5 spotter from Scienion (Berlin, Germany). Antibodies 
were printed at 1–2 mg/mL in 4 replicates, using PBS as printing buffer; the volume of spotted drops was 265 pL. 
Printed chips were placed in a humid chamber and incubated overnight at room temperature. Then they were 
blocked with 50 mM ethanolamine solution in 1 M TRIS/HCl pH 9, for 1 h, washed with pure water and dried 
under a nitrogen stream. Antibody arrays were first characterized by quantifying the immobilization density 
of the antibody probes using label-free film thickness measurement using IRIS27. IRIS images were taken and 
analyzed by Nexgenarrays LLC (Boston, MA) QC10 software. The QC software reports the probe density for the 
immobilized antibodies on the array. According to NanoSight quantifications, vesicles standard preparations 
were diluted in PBS to a concentration of 6.75E + 10 and 0 particles/mL and then 20 uL of each sample was incu-
bated overnight in static conditions on printed chips. Similarly, 20 uL of hCSF was incubated overnight at room 
temperature without any dilution. After incubation, chips were washed on a shaker with PBST (PBS with 0.05% 
Tween-20), PBS and pure water, rinsed in pure water and dried. Label-free SP-IRIS post-incubation scans were 
acquired and compared to previous corresponding detections using NVDX10 analysis software. The effective 
vesicle binding to the capture antibodies was obtained subtracting the signals measured after and before sample 
incubation. Net values from four spot replicates were averaged. Statistical analysis was performed with GraphPad 
Prism software.
SEM analysis of SP-IRIS substrates incubated with exosomes. For SEM imaging of captured 
exosomes the chips were fixed and stained after regular washing procedure but before final drying step. First, the 
exosomes were fixed with 0.1% gluteraldehyde in PBS for 15 minutes, then rinsed in Millipore water and dried. 
The chips were then stained in 1% osmium tetroxide in PBS for 30 minutes, then washed three times in Millipore 
water and dried under pure nitrogen stream. The stained chips were imaged using side scatter detector on a Zeiss 
Supra 55vp.
AFM analysis of SP-IRIS substrates incubated with exosomes. AFM measurements were performed 
on an NT-MDT instrument (SMENA head) working in tapping mode, in air and using a NSG-10 tip (240 kHz 
resonant frequency, 11.8 N/m force constant). Images of 20 × 20 um were acquired at 1024 points (19.5 nm step) 
to assure a proper mapping of the EVs. Images acquired at 2048 points showed an increase of nanoparticle size 
of less than 10%. The software Nova Px 3.4.0 and Gwyddion 2.44 were used for data analysis: for each acquired 
image, after its planarization, a proper mask was constructed to mark particles higher than 15 nm. The instrument 
was calibrated with a grating of 19 ± 1 nm height, thus the height accuracy of the nanoparticles mapped in the 
images is approximately 1 nm.
www.nature.com/scientificreports/
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Results and Discussion
Exosomes detection with SP-IRIS, SEM and AFM. The lack of high-throughput methods to assess EVs’ 
phenotype and determine their size and concentration in biological fluids inhibits progress in the validation and 
clinical use of this class of biomarkers. Standardization and consolidation of methods and protocols that display 
high feasibility, reliability and reproducibility would speed up the translation of basic scientific findings in clini-
cally relevant applications. In this work we demonstrate the use of an innovative technological platform termed 
Single Particle Interferometric Reflectance Imaging Sensor (SP-IRIS) for the high-throughput characterization of 
exosome concentration, relative size distribution and phenotyping in biological fluids28. The detection principle 
for SP-IRIS is based on the enhanced contrast in the scattering signal from particles captured on a silicon sub-
strate with a thin silicon dioxide layer (Fig. 1).
To detect and size nanoparticles, IRIS shines light from visible LED source onto nanoparticles bound to the 
sensor surface, which consists of a silicon dioxide layer on top of a silicon substrate. Interference of light reflected 
from the sensor surface is modified by the presence of particles producing a distinct signal that correlates to the 
size of the particle (Fig. 1A,B). The detection of low-index dielectric particles with diameters of 50 nm to 200 nm 
is shown in Fig. 1B28 demonstrating that the SP-IRIS signal correlates with the size of the particle.
In this work, EVs are captured on the surface of silicon chips through antibodies targeting exosomal markers. 
The chip’s glass surface is similar to that of a standard microarray slide and is coated with a functional poly-
mer, copoly-(DMA-NAS-MAPS)26, on which antibodies, specific for exosome surface antigens, are spotted in a 
microarray format. In Fig. 1 the analysis steps are shown. The process can be divided into three phases: antibody 
spotting, exosome capturing and image analysis (Fig. 1C–E). To demonstrate exosome capture and digital count-
ing, exosomes purified by ultracentrifugation from HEK 293 cell line cultures and characterized by NanoSight 
(Supporting Information, Figure SI1) were captured on anti-CD81 capture antibody spots. Dots of different con-
trast were clearly distinguished from the background after the chips were incubated with the HEK 293 exosome 
sample. EVs that, upon incubation, became visible on the spot surface, as shown in Fig. 2, were individually 
counted by an automated software and surrounded by circles which correspond to an area with contrast higher 
than the background and represent countable unlabeled individual exosomes (Fig. 2C–F). In the analysis phase 
particle counts are plotted as a function of their contrast and the distribution is shown in Fig. 2E,F.
Figure 1. Schematic representation of the SP-IRIS detection process. (A) SP-IRIS detection principle, 
monochromatic LED light illuminates the sensor surface and the interferometriclly enhanced nanoparticle 
scattering signature is captured on a CMOS camera. (B) Demonstrates SP-IRIS signal for polystyrene 
nanoparticles with a diameter from 50–200 nm which can be used to infer size of captured EVs. (C) Image of 
the SP-IRIS chip. (D) Low-magnification interferometric image showing microarray of immobilized capture 
probes. (E) SP-IRIS image of a capture probe. NVDX analysis software recognize capture spot and detects 
nanoparticles captured.
www.nature.com/scientificreports/
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To demonstrate that high contrast dots correspond to exosomes, scanning electron microscopy (SEM) and 
atomic force microscopy (AFM) images of the chip were taken and aligned with SP-IRIS images collected in 
dry conditions at end-point. In Fig. 3, a portion of capture antibody spot against CD81, after incubation with 
exosomes purified from HEK cell line (5.27E + 10 particles/mL) and analyzed in SP-IRIS, is compared to the 
same area observed in SEM. Nanoparticles (NPs) detected with SP-IRIS (Fig. 3A) are circled and correlate with 
the circles on the SEM image (Fig. 3B). SP-IRIS and SEM showed perfect correspondence for particles larger than 
Figure 2. Exosome capture, digital counting, and relative sizing. (A,B) Anti-CD81 capture probe image 
acquired before and after incubation with purified HEK293 cells derived exosomes. (C,D) Zoom-box of 
particles detected pre- and post-incubation. (E–F) Particle contrast histogram pre- and post-incubation.
Figure 3. Nanoparticle capture validation with SEM. (A) SP-IRIS image of exosomes being captured by 
anti-CD81 antibody. (B) Exosomes visualized by SEM of the same field-of-view for comparison. Scale bar is 1 
micron.
www.nature.com/scientificreports/
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65 nm, while smaller particles are detectable only with electron microscopy, which is consistent with detection 
limits of both analytical techniques. The particle sizes detected by SP-IRIS ranged between 65–85 nm as measured 
using the SEM image. No particles were detected with either SP-IRIS or SEM on CD81 antibody spot incubated 
with exosome depleted HEK293 culture media (Supporting Information, Figure SI2).
In Fig. 4, a part of anti-CD81 spot is analyzed by SP-IRIS and aligned with an AFM image of the same area. 
SP-IRIS images were acquired before (Supporting Information, Figure SI3) and after (Fig. 4A) incubation with 
exosomes purified from HEK cell line. Red circles in Fig. 4A correspond to vesicles detected after sample incuba-
tion. Figure 4B shows the same spot area imaged with AFM.
In a number of publications29,30, the height of exosomes measured by AFM is as low as 10–20 nm. The size of ves-
icles on images performed on dry chips (nanoparticles are surrounded by air) may be an underestimation of the real 
size due to the drying process. Particles with a height profile in excess of 15 nm in the AFM image are considered 
exosomes and lateral dimension was measured to be between 80–140 nm + /− 20 nm. In the image of Fig. 4B the 
particles higher than 15 nm, marked in blue coincide with the spots of higher contrast, surrounded by yellow circles, 
detected by SP-IRIS (red circles). The close up of the area in the green square, shown in Fig. 4C provides a higher 
resolution AFM image of the surface. SP-IRIS detects vesicles that appear to be higher than 15 nm (Supporting 
Information SI4), whereas smaller particles go undetected in SP-IRIS. No particles were detected on CD81 antibody 
spot incubated with exosome depleted HEK293 culture media (Supporting Information, Figure SI5).
SP-IRIS phenotyping of exosomes purified from HEK cell.  Three capture antibodies against the exo-
somal biomarkers CD81, CD63 and CD9 were arrayed on the same chip together with a negative control IgG 
in order to evaluate the vesicle tetraspanin expression profile (Supporting Information, Figure SI6). Exosomes 
purified from HEK cell line and the EV depleted supernatant (SN, as negative control) were analyzed with NTA 
(Supporting Information, Figure SI1) to determine the particle concentration in each sample. Exosomes were 
diluted in PBST at 5.27 and 2.64E + 10 particles/mL. In Fig. 5, the histogram reports the number of vesicles, per 
square millimeter, detected by SP-IRIS. The results indicate higher expression of CD81 tetraspanin compared 
to CD63 and CD9. As expected, the EVs depleted SN showed no binding to CD81 and CD9, but low binding 
to CD63. No significant particles were counted on control IgG spots. The relative size of the exosomes captured 
by CD81, CD9, and CD63 was measured using SP-IRIS through particle contrast quantification (Supporting 
Information, Figure SI6). Based on polystyrene nanoparticle response (Fig. 1B), the estimated mean diameter 
of the exosomes is 55–65 nm. Also much larger particles were observed whose diameter is comparable to that 
measured by AFM and SEM.
By establishing a dilution curve with exosome standards the user can determine the EVs concentration for 
different surface phenotype using a single microarray. The exosomes detected by the tetraspanin probes showed 
similar size distribution as inferred by the measured contrast distribution of the particle in the SP-IRIS image 
(Supporting Information, Figure SI6).
Dilution curves of exosomes purified from HEK cell line and assay limit of detection.  Exosomes 
purified from HEK cell line and EV depleted supernatant (SN, negative control) were characterized by NTA 
(Supporting Information, Figure SI1) in order to evaluate the particle content in each sample. Several dilutions 
ranging from 6.8E + 10 to 9E + 09 particles/mL were incubated on silicon chips where capture antibodies against 
CD81 and CD63 as well as Rabbit IgG (R IgG, as negative control) were arrayed. As NTA was unable to detect any 
particle in the SN, this sample was used as control.
Figure 4. Exosomes purified from HEK cell line, captured with anti- CD81 antibody on silicon chip and detected 
by SP-IRIS (A) and AFM (B,C). (A) SP-IRIS Image of the anti-CD81 spot incubated with a suspension of exosomes 
(6.75E + 10 exosomes/mL), the red circles highlight the countable nanoparticles. (B) AFM image of the same 
spot area: the blue dots identify particles larger than 15 nm; the yellow circles show in image (B) perfectly match 
the particles detected by SP-IRIS in image (A). (C) Zoom in area of the anti-CD81 spot shown in the green frame 
highlights the particles larger than 15 nm in height detected by AFM and SP-IRIS. Particles smaller than 15–10 nm 
are detectable only with AFM as they are below SP-IRIS detection limit.
www.nature.com/scientificreports/
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Figure 6 shows the dose-response curves for particles counted on each antibody by SP-IRIS. The regression 
area around each line corresponds to 95% confidence interval of the data. As expected, no particles were detected 
on the negative control R IgG. A linear correlation was observed between exosome concentration and particle 
counts with excellent correlation coefficients (R2) for both capture antibodies: CD81 (0.93) and CD63 (0.97). By 
using the equations of the extrapolated lines, detection limits were calculated for both tetraspanins: 3.94E + 09 
and 5.07E + 09 particles/mL, respectively for CD81 and CD63.
Detection limit comparison between SP-IRIS target specific capture and NTA warrants further investigation. 
NTA measures non-specifically all particles in a solution, while SP-IRIS is only measuring the subpopulation 
based on the capture antibody target on the sensor’s surface. It has been reported in the literature that exosome 
preparations by pelleting through ultracentrifugation contain a heterogeneous population of exosomes with 
different proteomic and molecular composition31. Further experiments are required using exosome standard 
with known surface marker composition to allow direct comparison of analytical sensitivity between NTA and 
SP-IRIS.
SP-IRIS detection and quantification of exosomes in human cerebrospinal fluid (hCSF).  As 
exosomes are vesicles released by every kind of cell, they have been found in several human biological fluids, 
such as urine, saliva, blood as well as cerebrospinal fluid (CSF)32. Determining the concentration and size of 
exosomes in human CSF (hCSF) is not trivial, because the available sample volume is usually too small to allow 
analysis either with NTA or ELISA. In this work, hCSF has been used to demonstrate the potential of clinical 
utility of the technique. A conventional way to characterize exosomes in hCSF requires serial centrifugations in 
a density gradient followed by a characterization by Western blot. We first characterized exosomes in hCSF by a 
conventional approach and the results are shown in Fig. 7A,B. The exosomal proteins TSG101 and flotillin were 
present in the exosomal fractions and not in CSF depleted of exosomes (Neat CSF) while cystatin C (CysC), a 
soluble protein which is also secreted in association with exosomes11, was present in both fractions. Conversely, 
calnexin, an endoplasmic reticulum residential protein, was absent from both fractions indicating the absence 
of cell fragments contamination (Fig. 7A). Furthermore TSG101 was used as a marker to identify the fractions 
containing exosomes in a sucrose gradient. The results of Fig. 7B confirm that the 1.13 and 1.14 g/mL sucrose 
fractions are enriched in exosomes.
Figure 5. Exosome Phenotyping. Exosomes, isolated from HEK fibroblast cells and EV depleted supernatant, 
captured with antibodies against CD81, CD63, CD9 and IgG negative control and detected by SP-IRIS.
Figure 6. Dilution curve of exosomes purified from HEK cell line and detected with SP-IRIS. A good 
correlation can be observed for both capture antibodies CD63 (yellow line, R2 0.97) and CD81 (blue line, R2 
0.93); no particles were detected on the negative control R IgG (red line). The bright area around the regression 
line corresponds to the 95% confidence interval. Based on line equations, limits of detection (LOD) were 
calculated, resulting in 5.07E + 09 particles/mL for CD63 antibody and 3.94E + 09 particles/mL for CD81 
antibody.
www.nature.com/scientificreports/
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While the analysis reported above, required 1.8 mL of hCSF, only 20 uL of sample were required by SP-IRIS. 
The 20 uL of hCSF were incubated over-night, without any dilution, on chips multiplexed with antibodies against 
tetraspanins (CD81 and CD63) as exosome markers and CD171, a cell adhesion molecule highly expressed by 
neuronal cells commonly used to capture exosomes of neural sources from blood33, together with a control IgG 
antibody. As negative control, an artificial CSF was used. SP-IRIS images after hCSF incubation were compared 
with pre-scan acquisitions and the data analyzed by NVDX10 Analysis Software. Figure 8 reports the results of 
the SP-IRIS label-free assay on hCSF. Signals on CD81 and CD63 are different, indicating that not all tetraspanins 
are expressed equally. Also CD171 showed higher binding in hCSF than negative control sample.
Considering the average particle densities on CD81 and using the calibration curves previously obtained for 
each capture antibody (Fig. 6), an average concentration of about 2E + 10 particles/mL in hCSF was extrapolated.
Conclusions
The characterization and quantification of circulating as well as cell culture-derived exosomes based on expres-
sion of specific exosomal biomarkers (e.g. tetraspanins, annexins and heat shock proteins) is currently performed 
by running size and concentration measurements on vesicles and immunoproteomic analyses in parallel and 
then correlating the results. Size and concentration measurements are performed with Electron Microscopy, 
Figure 7. (A) Western blot analysis of exosomes isolated from 1.8 ml of hCSF and neat hCSF: the exosomal 
markers TSG101 and flotillin marked the exosomes fraction and not neat CSF, cystatin C marked both fractions 
and calnexin was not detected. (B) Sucrose gradient fractions of exosomal preparations from hCSF were 
immunoblotted with the TSG101 monoclonal antibody. TSG101 marked the exosomes-positive fractions 
(corresponding to 1.13 and 1.14 g/mL sucrose). HEK cells lysate was used as positive control. Western blot gels 
have been cropped to show only the relevant protein bands. Complete figures can be found as Supplementary, 
Figure SI 7.
Figure 8. SP-IRIS label-free assay on human hydrocephalus CSF sample and artificial CSF. The expression 
of the typical exosomal biomarkers CD81 CD63 as well as the neural adhesion protein CD171 is significantly 
different than in the artificial CSF, negative control. An additional negative control, a non correlated IgG, shows 
a low level of non-specific binding. Each multiplexed chip was run in duplicate independent replicate tests.
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Nanoparticle Tracking Analysis (NTA) (NanoSight) or qNano (Izon Science Ltd). However, these techniques can 
only be used to characterize pure EVs as they do not discriminate nanoparticles of different origin, for instance 
exosomes from protein aggregates or lipids of the same size. Even though they can objectively define the EVs 
size range and concentration, they are restricted in their ability to simultaneously phenotype them. Therefore, 
phenotyping is done in parallel using immunoproteomic techniques like immunoblotting or by a novel, high res-
olution, flow cytometric analysis where exosomes are captured on antibody-coated latex beads16. This latter type 
of analysis allows the simultaneous evaluation of multiple parameters on single exosomes by a multicolor labeling 
strategy. However, conventional flow cytometry and Western Blotting demand large amounts of proteins isolated 
by extensive and time-consuming standard isolation procedures.
Therefore, direct counting, sizing and phenotyping of EVs will streamline both analysis and characterization. 
SP-IRIS platform can perform phenotyping and, potentially, sizing at the single exosome level without the need 
to correlate two separate measurements, which could be inaccurate, especially when done on non-purified sam-
ples because exosomal marker targets could be in soluble form not associated with nanoparticles. SP-IRIS can 
enumerate, estimate particle size, and phenotype exosomes from purified samples from cell culture, or directly 
from just 20 uL of a clinical sample such as hCSF. A detection limit of 3.94E + 09 particles/mL was achieved for 
purified nanoparticles from HEK 293 cell lines, as quantified using NTA. Exosome quantification by NTA is 
non-specific and therefore concentration of nanoparticles measured is an overestimate of the exosome concentra-
tion. Therefore, further experiments need to be done to understand the detection limits differences. In addition, 
we demonstrated that SP-IRIS can potentially phenotype exosomes directly from hCSF, employing a very small 
sample volume.
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